We are an information and analytics company focused on pharmaceutical reimbursement.

We are an information and analytics company focused on pharmaceutical reimbursement.

News & Updates

Real Endpoints Recent Developments

BioCenturyTV Interviews Real Endpoints CEO on Determining Value in Specialty Drugs

Posted by Julie Eagle on Dec 9, 2014

BioCentury TV Interviews Roger Longman, CEO of Real Endpoints as part of a series on the high cost of drugs.  In Part I, Longman addresses the importance of valuing drug therapy. In his second interview, Longman discusses the changing trajectory for specialty drugs....

Learn More

We Need More Transparency on the Cost of Speciality Drugs

Posted by Julie Eagle on Nov 7, 2014

Harvard Business Review, November 4, 2014 We Need More Transparency on the Cost of Speciality Drugs, by Robert Galvin, MD and Roger Longman Decisions about which drugs to include in and exclude from formularies are part of a larger problem. As a society, we have...

Learn More

Move over Gilead? AbbVie could bring serious competition to HCV market.

Posted by Julie Eagle on Oct 13, 2014

Gilead’s Harvoni might be the top overall performer, says RxScorecard™, but a discounted Triple regimen from AbbVie could mount major challenge. Gilead’s Harvoni (sofosbuvir/ledipasvir combination) is the top overall scorer, according to RxScorecard, a drug-value...

Learn More

Roger Longman, Guest Commentary, BioCentury, Week of October 6, 2014

Posted by Julie Eagle on Oct 10, 2014

Price Cuts in HCV by Roger Longman, CEO, Real Endpoints. If you’ve heard or read anything about HCV, you’ll know the costs of covering the large population are very high – and will get worse. That’s certainly the subtext in announcements from...

Learn More

Roger Longman, Guest Commentary, BioCentury, Week of August 4, 2014

Posted by Julie Eagle on Aug 11, 2014

Biopharma’s Echo Chamber by Roger Longman, CEO, Real Endpoints. Either pharma helps its customers create the standards on which the full value of their drugs will be measured relative to their competitors – or they’ll have it done for them. Please...

Learn More

Roger Longman, Guest Commentary, BioCentury, Week of June 9, 2014

Posted by Julie Eagle on Jun 10, 2014

Cost Steamroller by Roger Longman, CEO, Real Endpoints. The challenge for biopharma companies is to make sure that cost is only one component of the assessment. Please click here to learn more and access the...

Learn More